Sanofi-Aventis withdraws rimonabant NDA

Share this article:

Sanofi-Aventis said Friday it has decided to withdraw its New Drug Application (NDA) for weight-loss treatment rimonabant in the US.

The decision came just a week and a half after an advisory panel of outside experts recommended that the FDA not approve rimonabant because the drug’s possible connection to suicidal behavior and other psychological side effects in some patients.
 
Although the FDA does not have to follow the advice of its outside expert panels, it often does. The FDA was scheduled to issue a final decision on the drug July 27.
 
Sanofi-Aventis said in a statement it will work towards re-submitting rimonabant at a future date.

Sanofi-Aventis had hoped rimonabant, also known by the brand names Acomplia and Zimulti, would be the drugmaker's next billion-dollar earner. But Sanofi's own clinical studies have raised concerns among regualtors about an increased rate of psychiatric adverse events among patients taking rimonabant including depression, anxiety and insomnia.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...